Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Inhibition of c-MET upregulates PD-L1 expression in lung adenocarcinoma.

Sun X, Li CW, Wang WJ, Chen MK, Li H, Lai YJ, Hsu JL, Koller PB, Chan LC, Lee PC, Cheng FJ, Yam C, Chen GY, Hung MC.

Am J Cancer Res. 2020 Feb 1;10(2):564-571. eCollection 2020.

2.

Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models.

Han L, Zhang Q, Dail M, Shi C, Cavazos A, Ruvolo VR, Zhao Y, Kim E, Rahmani M, Mak DH, Jin SS, Chen J, Phillips DC, Koller PB, Jacamo R, Burks JK, DiNardo C, Daver N, Jabbour E, Wang J, Kantarjian HM, Andreeff M, Grant S, Leverson JD, Sampath D, Konopleva M.

Haematologica. 2020 Mar;105(3):697-707. doi: 10.3324/haematol.2018.205534. Epub 2019 May 23.

3.

MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1.

Li H, Li CW, Li X, Ding Q, Guo L, Liu S, Liu C, Lai CC, Hsu JM, Dong Q, Xia W, Hsu JL, Yamaguchi H, Du Y, Lai YJ, Sun X, Koller PB, Ye Q, Hung MC.

Gastroenterology. 2019 May;156(6):1849-1861.e13. doi: 10.1053/j.gastro.2019.01.252. Epub 2019 Jan 31.

PMID:
30711629
4.

Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship.

Koller PB, Kantarjian HM, Nogueras-Gonzalez GM, Jabbour E, Verstovsek S, Borthakur G, Estrov Z, Wierda WG, Garcia-Manero G, Ferrajoli A, Ravandi F, O'Brien SM, Cortes JE.

Cancer. 2017 Feb 15;123(4):609-616. doi: 10.1002/cncr.30362. Epub 2016 Oct 20.

Supplemental Content

Loading ...
Support Center